Sezen Gülseli Berivan, Boyalı Osman, Karip Burak, Aktaş Selman, Savrunlu Eyüp Can, Chasan Mourat, Kaplan Necati, Civelek Erdinç, Kabataş Serdar
Giresun Training and Research Hospital, Clinic of Neurosurgery, Giresun, Türkiye.
University of Health Sciences Türkiye, Gaziosmanpaşa Training and Research Hospital, Clinic of Neurosurgery, İstanbul, Türkiye.
Turk J Anaesthesiol Reanim. 2025 May 14. doi: 10.4274/TJAR.2025.241831.
This retrospective study aimed to evaluate and compare the clinical efficacy of intradiscal ozone therapy (OT) against a combination therapy of ozone and platelet-rich plasma (PRP) in patients diagnosed with intervertebral disc degeneration (IVDD).
The study included a cohort of 50 patients, divided equally into two groups of 25, who received either intradiscal OT or ozone + PRP combination therapy between February 2022 and February 2023. The sample comprised 20 females and 30 males, with ages ranging from 19 to 76 years (mean age 48.8). Pain intensity was measured using the visual analog scale (VAS), while disability levels were assessed using the oswestry disability index (ODI) prior to treatment and at 1, 3, and 6 months post-treatment. Additionally, lumbar magnetic resonance imaging was conducted at the 3-month mark post-treatment, with evaluations based on the Pfirrmann disc degeneration classification.
Significant improvement in both VAS and ODI scores was observed in both treatment groups ( < 0.001). The ozone + PRP combination therapy group exhibited no statistically significant difference in VAS and ODI scores compared to the ozone-only group ( > 0.05).
Intradiscal OT and the ozone + PRP combination therapy represent effective minimally invasive treatment options for patients suffering from IVDD, yielding substantial clinical benefits with minimal side effects. That is why it is suggested as a potential preferred therapeutic approach prior to the consideration of surgical interventions.
本回顾性研究旨在评估和比较椎间盘内臭氧疗法(OT)与臭氧联合富血小板血浆(PRP)疗法对诊断为椎间盘退变(IVDD)患者的临床疗效。
该研究纳入了50例患者,平均分为两组,每组25例,在2022年2月至2023年2月期间分别接受椎间盘内OT或臭氧+PRP联合治疗。样本包括20名女性和30名男性,年龄在19至76岁之间(平均年龄48.8岁)。治疗前及治疗后1个月、3个月和6个月,使用视觉模拟量表(VAS)测量疼痛强度,使用奥斯威斯利功能障碍指数(ODI)评估功能障碍水平。此外,在治疗后3个月进行腰椎磁共振成像,根据Pfirrmann椎间盘退变分级进行评估。
两个治疗组的VAS和ODI评分均有显著改善(<0.001)。与单纯臭氧组相比,臭氧+PRP联合治疗组的VAS和ODI评分无统计学显著差异(>0.05)。
椎间盘内OT和臭氧+PRP联合治疗是IVDD患者有效的微创治疗选择,临床疗效显著且副作用最小。因此,建议在考虑手术干预之前将其作为潜在的首选治疗方法。